Search
Eisai has shelled out US$388 million for the pertinent agreement. This sum encompasses an upfront payment of US$75 million, regulatory milestone payments amounting to US$80.01 million, sales milestone payments totaling US$233.33 million, and double-digit percentage sales royalties. Serplulimab has already received approval for the treatment of lung cancer and esophageal squamous cell carcinoma, and there are multiple indications currently under clinical development. Henlius is looking forward to robust growth in the next five years, which is expected to fuel its global expansion. The licensing of PD-1 in the Japanese market marks a significant phased milestone for the company, as it anticipates launching over 10 products globally in the coming years.
-
C114 Communication Network -
Communication Home
